Business Description
Eli Lilly and Co
NAICS : 325412
SIC : 2834
ISIN : US5324571083
Compare
Compare
Traded in other countries / regions
LLY.USALLY.CanadaLILY34.BrazilLLY.ArgentinaLLY.GermanyLLY.Mexico1LLY.ItalyLLYCL.ChileLLYC.AustriaLLY.SwitzerlandLLY.BulgariaLLYz.UKLLY.France IPO Date
2023-11-13Description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.11 | |||||
| Equity-to-Asset | 0.19 | |||||
| Debt-to-Equity | 2.19 | |||||
| Debt-to-EBITDA | 2.49 | |||||
| Interest Coverage | 21.8 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 8.38 | |||||
| Beneish M-Score | -1.9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12 | |||||
| 3-Year EBITDA Growth Rate | -1 | |||||
| 3-Year EPS without NRI Growth Rate | -7.3 | |||||
| 3-Year Book Growth Rate | 26.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 68.26 | |||||
| Future 3-5Y Total Revenue Growth Rate | 27.59 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.83 | |||||
| 9-Day RSI | 53.68 | |||||
| 14-Day RSI | 49.72 | |||||
| 6-1 Month Momentum % | 10.96 | |||||
| 12-1 Month Momentum % | 53.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.27 | |||||
| Quick Ratio | 0.97 | |||||
| Cash Ratio | 0.14 | |||||
| Days Inventory | 287.39 | |||||
| Days Sales Outstanding | 83.01 | |||||
| Days Payable | 124.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.64 | |||||
| Dividend Payout Ratio | 0.38 | |||||
| 3-Year Dividend Growth Rate | 15.2 | |||||
| Forward Dividend Yield % | 0.65 | |||||
| 5-Year Yield-on-Cost % | 1.29 | |||||
| 3-Year Average Share Buyback Ratio | 2 | |||||
| Shareholder Yield % | -0.66 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 80.91 | |||||
| Operating Margin % | 37.02 | |||||
| Net Margin % | 20.48 | |||||
| FCF Margin % | -5.55 | |||||
| ROE % | 66.85 | |||||
| ROA % | 12.55 | |||||
| ROIC % | 24.99 | |||||
| ROC (Joel Greenblatt) % | 68.24 | |||||
| ROCE % | 25.38 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 85.98 | |||||
| Forward PE Ratio | 35.33 | |||||
| PE Ratio without NRI | 78.21 | |||||
| Shiller PE Ratio | 140.79 | |||||
| PEG Ratio | 7.31 | |||||
| PS Ratio | 17.6 | |||||
| PB Ratio | 50.26 | |||||
| Price-to-Tangible-Book | 370 | |||||
| Price-to-Operating-Cash-Flow | 119.3 | |||||
| EV-to-EBIT | 68.5 | |||||
| EV-to-Forward-EBIT | 30.47 | |||||
| EV-to-EBITDA | 59.36 | |||||
| EV-to-Forward-EBITDA | 28.15 | |||||
| EV-to-Revenue | 18.18 | |||||
| EV-to-Forward-Revenue | 12.72 | |||||
| EV-to-FCF | -326.49 | |||||
| Price-to-Projected-FCF | 13.81 | |||||
| Price-to-Median-PS-Value | 2.98 | |||||
| Price-to-Peter-Lynch-Fair-Value | 9.87 | |||||
| Price-to-Graham-Number | 35.86 | |||||
| Earnings Yield (Greenblatt) % | 1.46 | |||||
| FCF Yield % | -0.32 | |||||
| Forward Rate of Return (Yacktman) % | 8.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eli Lilly and Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 37,450.558 | ||
| EPS (TTM) (€) | 8.512 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 49.72 | ||
| 14-Day ATR (€) | 28.016454 | ||
| 20-Day SMA (€) | 737.815 | ||
| 12-1 Month Momentum % | 53.82 | ||
| 52-Week Range (€) | 516 - 886.1 | ||
| Shares Outstanding (Mil) | 899.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eli Lilly and Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eli Lilly and Co Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Eli Lilly and Co Frequently Asked Questions
What is Eli Lilly and Co(MIL:1LLY)'s stock price today?
The current price of MIL:1LLY is €754.80. The 52 week high of MIL:1LLY is €886.10 and 52 week low is €516.00.
When is next earnings date of Eli Lilly and Co(MIL:1LLY)?
The next earnings date of Eli Lilly and Co(MIL:1LLY) is 2025-02-06 Est..
Does Eli Lilly and Co(MIL:1LLY) pay dividends? If so, how much?
The Dividend Yield %  of Eli Lilly and Co(MIL:1LLY) is 0.64% (As of Today), Highest Dividend Payout Ratio of Eli Lilly and Co(MIL:1LLY) was 0.72. The lowest was 0.37. And the median was 0.49. The  Forward Dividend Yield % of Eli Lilly and Co(MIL:1LLY) is 0.65%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers